Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Harvard Business School
AstraZeneca
McKesson
Colorcon

Last Updated: August 19, 2022

Investigational Drug Information for Anamorelin


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for Anamorelin?

Anamorelin is an investigational drug.

There have been 11 clinical trials for Anamorelin. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2011.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Cachexia, and Lung Neoplasms. The leading clinical trial sponsors are Helsinn Therapeutics (U.S.), Inc, Helsinn Healthcare SA, and National Cancer Institute (NCI).

Recent Clinical Trials for Anamorelin
TitleSponsorPhase
Anamorelin Study for Advanced Pancreatic CancerHelsinn Healthcare SAPhase 2
Anamorelin Study for Advanced Pancreatic CancerQuartesian LLCPhase 2
Anamorelin Study for Advanced Pancreatic CancerLahey ClinicPhase 2

See all Anamorelin clinical trials

Clinical Trial Summary for Anamorelin

Top disease conditions for Anamorelin
Top clinical trial sponsors for Anamorelin

See all Anamorelin clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Harvard Business School
AstraZeneca
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.